Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 4
2004 4
2005 10
2006 4
2007 3
2008 2
2009 7
2010 6
2011 9
2012 13
2013 12
2014 17
2015 15
2016 6
2017 13
2018 11
2019 4
2020 11
2021 16
2022 9
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Innate immune cell activation after HIV-1 vaccine administration is associated with increased antibody production.
N'guessan KF, Machmach K, Swafford I, Costanzo MC, Wieczorek L, Kim D, Akapirat S, Polonis VR, Pitisuttithum P, Nitayaphan S, Gurunathan S, Sinangil F, Chariyalertsak S, Ake JA, O'connell RJ, Vasan S, Paquin-Proulx D. N'guessan KF, et al. Among authors: pitisuttithum p. Front Immunol. 2024 Feb 13;15:1339727. doi: 10.3389/fimmu.2024.1339727. eCollection 2024. Front Immunol. 2024. PMID: 38420129 Free PMC article. Clinical Trial.
The Brighton collaboration standardized module for vaccine benefit-risk assessment.
Levitan B, Hadler SC, Hurst W, Izurieta HS, Smith ER, Baker NL, Bauchau V, Chandler R, Chen RT, Craig D, King J, Pitisuttithum P, Strauss W, Tomczyk S, Zafack J, Kochhar S. Levitan B, et al. Among authors: pitisuttithum p. Vaccine. 2024 Feb 6;42(4):972-986. doi: 10.1016/j.vaccine.2023.09.039. Epub 2023 Dec 21. Vaccine. 2024. PMID: 38135642 Free article.
Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety.
Restrepo J, Herrera T, Samakoses R, Reina JC, Pitisuttithum P, Ulied A, Bekker LG, Moreira ED, Olsson SE, Block SL, Hammes LS, Laginha F, Ferenczy A, Kurman R, Ronnett BM, Stoler M, Bautista O, Gallagher NE, Salituro G, Ye M, Luxembourg A. Restrepo J, et al. Among authors: pitisuttithum p. Pediatrics. 2023 Oct 1;152(4):e2022060993. doi: 10.1542/peds.2022-060993. Pediatrics. 2023. PMID: 37667847
Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Muangnoicharoen S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, Lawpoolsri S, Jongkaewwattana A, Thitithanyanont A, Luvira V, Chinwangso P, Thanthamnu N, Chantratita N, Lim JK, Anh Wartel T, Excler JL, Ryser MF, Leong C, Mak TK, Pitisuttithum P. Muangnoicharoen S, et al. Among authors: pitisuttithum p. Vaccine. 2023 Jul 19;41(32):4648-4657. doi: 10.1016/j.vaccine.2023.06.043. Epub 2023 Jun 15. Vaccine. 2023. PMID: 37344265 Free PMC article. Clinical Trial.
Considerations for unblinding individual study participants during vaccine trials.
Halsey N, Evans S, Santosham M, Hacker A, Edwards KM, Chandler RE, Dudley MZ, Dekker CL; members of the SPEAC meta-DSMB; Al-Abri S, Arora N, Buttery J, Dodoo A, Eskola J, Heininger U, Jee Y, Khuri N, Obaro S, Orenstein W, Pitisuttithum P, Safadi M, Whitney CG, Black S. Halsey N, et al. Among authors: pitisuttithum p. Vaccine. 2023 May 22;41(22):3399-3402. doi: 10.1016/j.vaccine.2023.04.033. Epub 2023 Apr 28. Vaccine. 2023. PMID: 37121805 Free article. Review.
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination.
Carreño JM, Raskin A, Singh G, Tcheou J, Kawabata H, Gleason C, Srivastava K, Vigdorovich V, Dambrauskas N, Gupta SL, González Domínguez I, Martinez JL, Slamanig S, Sather DN, Raghunandan R, Wirachwong P, Muangnoicharoen S, Pitisuttithum P, Wrammert J, Suthar MS, Sun W, Palese P, García-Sastre A, Simon V, Krammer F. Carreño JM, et al. Among authors: pitisuttithum p. Sci Transl Med. 2023 Feb 15;15(683):eabo2847. doi: 10.1126/scitranslmed.abo2847. Epub 2023 Feb 15. Sci Transl Med. 2023. PMID: 36791207 Free article.
Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?
Horvath A, Rogers L, Pollakis G, Baranov O, Pieroth N, Joseph S, Chachage M, Heitzer A, Maganga L, Msafiri F, Joachim A, Viegas E, Eller LA, Kibuuka H, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Dhitavat J, Premsri N, Fidler S, Shattock RJ, Robb ML, Weber J, McCormack S, Munseri PJ, Lyamuya E, Nilsson C, Kroidl A, Hoelscher M, Wagner R, Geldmacher C, Held K. Horvath A, et al. Among authors: pitisuttithum p. Front Immunol. 2023 Jan 9;13:1075606. doi: 10.3389/fimmu.2022.1075606. eCollection 2022. Front Immunol. 2023. PMID: 36741409 Free PMC article.
Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.
Niyomnaitham S, Jongkaewwattana A, Meesing A, Pinpathomrat N, Nanthapisal S, Hirankarn N, Siwamogsatham S, Kirdlarp S, Chaiwarith R, Lawpoolsri S, Phanthanawiboon S, Thitithanyanont A, Hansasuta P, Chaiyaroj S, Pitisuttithum P. Niyomnaitham S, et al. Among authors: pitisuttithum p. Int J Infect Dis. 2023 Apr;129:19-31. doi: 10.1016/j.ijid.2023.01.022. Epub 2023 Jan 20. Int J Infect Dis. 2023. PMID: 36682680 Free PMC article. Clinical Trial.
183 results